Truist Securities Reiterates Hold Rating on Amgen (AMGN), 'Competition for OX40 in atopic dermatitis narrowing'
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Hold rating and $263.00 price target on Amgen (NASDAQ: AMGN).The analyst comments "Competition ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
